Pharmaceutical Representative

Pharmaceutical Representative articles

1,600 total articles
A monthly magazine focusing on sales insight and development within the pharmaceutical sales field.

Pharmaceutical Representative back issues:

20092007
2008

Recently added articles from Pharmaceutical Representative:

Authorized generics agreements to increase.(Pharma News)
September 1, 2009 ... The number of authorized generics (AG) agreements is likely to grow as pharma continues to converge with generics companies, a new report from Datamonitor claims. AG agreements are considered more "potent" in the U.S. market because market...

Amgen will collaborate with GlaxoSmithKline to commercialize Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries.(The Industry)
September 1, 2009 ... Amgen will collaborate with GlaxoSmithKline to commercialize Amgen's monoclonal antibody denosumab for postmenopausal osteoporosis in Europe, Australia, New Zealand and Mexico once the product is approved in these countries. Amgen will retain...

New NIH leader backs personalized medicine.(Pharma News)
September 1, 2009 ... The driving force behind NIH's Human Genome Project, Francis Collins, has been named head of the National Institutes of Health. Collins is experienced in managing large research projects and big budgets and m making friends on Capitol Hill....

The European Medicines Agency's Committee for Medicinal Products for Human Use concluded that changes to the prescribing advice for Sanofi-Aventis's Lantus (insulin glargine [rDNA] injection) are not necessary.(Global Report)
September 1, 2009 ... The European Medicines Agency's Committee for Medicinal Products for Human Use concluded that changes to the prescribing advice for Sanofi-Aventis's Lantus (insulin glargine [rDNA] injection) are not necessary. Recently published studies have...

FDA gives Xolair concerns an airing.(FDA Update)
September 1, 2009 ... The U.S. Food and Drug Administration announced that it is conducting a safety review of Xolair (omalizumab), a drug used to treat certain adults and adolescents with moderate-to-severe persistent asthma. Reviewers are looking for a...